New strategies for immunosuppression: Interfering with cytokines by targeting the Jak/Stat pathway

Current Opinion in Rheumatology

Volumn 17, Issue 3, 2005, Pages 305-311

  O'Shea, John J ^a,d   Park, Heiyoung ^a   Pesu, Marko ^a   Borie, Dominic ^b   Changelian, Paul ^c  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytokines; Interleukin; Janus kinase 3; Protein inhibitors of activated stats; Severe combined immunodeficiency; Signal transducer and activator of transcription pathway; Suppressors of cytokine signaling

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ANTIBIOTIC AGENT; CT 2576; CT 5589; CYCLOSPORIN A; CYTOKINE; CYTOKINE RECEPTOR; DNA BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LEFLUNOMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OCTYLAMINOUNDECYLDIMETHYLXANTINE; PNU 156804; PYRIDONE DERIVATIVE; STAT PROTEIN; UNCLASSIFIED DRUG; UNDECYLPRODIGIOSIN ANTIBOTIC AGENT; WHI P 154; XANTHINE DERIVATIVE;

ANEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL FUNCTION; ENTERITIS; ENZYME INHIBITION; GENE TARGETING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TRANSCRIPTION INITIATION;

ANIMALS; CYTOKINES; DNA-BINDING PROTEINS; DRUG DESIGN; GUIDELINES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 1; PROTEIN-TYROSINE KINASES; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 18144428686     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000160781.07174.db     Document Type: Review

References (71)

1. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163-196.
2. Steinman L. Immune therapy for autoimmune diseases. Science 2004; 305:212-216.
3. Boulay JL, O'Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003; 19:159-163.
4. Gadina M, Hilton D, Johnston JA, et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 2001; 13:363-373.
5. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-1421.
6. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16:293-322.
7. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109(Suppl):S121-S131.
8. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73:147-157.
9. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167:1-5.
10. Leonard WJ, Noguchi M, Russell SM, et al. The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev 1994; 138:61-86.
11. Notarangelo LD, Giliani S, Mella P, et al. Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model. Immunobiology 2000; 202:106-119.
12. Buckley RH. The multiple causes of human SCID. J Clin Invest 2004; 114:1409-1411.
13. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343:1313-1324.
14. Candotti F, Notarangelo L, Visconti R, et al. Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J Clin Invest 2002; 109:1261-1269.
15. Puel A, Ziegler SF, Buckley RH, et al. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20:394-397.
16. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002; 99:3892-3904.
17. Becker TC, Wherry EJ, Boone D, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002; 195:1541-1548.
18. Goldrath AW, Sivakumar PV, Glaccum M, et al. Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 2002; 195:1515-1522.
19. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002; 100:3633-3638.
20. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13:169-183.
21. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933-944.
22. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003; 23:147-161.
23. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298:1630-1634.
24. Witthuhn BA, Silvennoinen O, Miura O, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994; 370:153-157.
25. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994; 370:151-153.
26. Miyazaki T, Kawahara A, Fujii H, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994; 266:1045-1047.
27. Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994; 266:1042-1045.
28. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270:797-800.
29. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377:65-68.
30. Mella P, Schumacher RF, Cranston T, et al. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain. Hum Mutat 2001; 18:355-356.
31. Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat 2001; 18:255-263.
32. Candotti F, Oakes SA, Johnston JA, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997; 90:3996-4003.
33. Roberts JL, Lengi A, Brown SM, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 2003; 103:2009-2018.
34. O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3:555-564. This is a comprehensive review of Jak3 inhibitors as well as other issues pertaining to inhibiting Jaks and Stats.
35. Adams C, Aldous DJ, Amendola S, et al. Mapping the kinase domain of Janus Kinase 3. Bioorg Med Chem Lett 2003; 13:3105-3110.
36. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302:875-878.
37. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93:385-395.
38. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4:392-397.
39. Ferrari-Lacraz S, Zanelli E, Neuberg M, et al. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 2004; 173:5818-5826.
40. Townsend JM, Fallon GP, Matthews JD, et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000; 13:573-583.
41. Temann UA, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest 2002; 109:29-39.
42. McMillan SJ, Bishop B, Townsend MJ, et al. The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 2002; 195:51-57.
43. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10:507-512.
44. Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13:561-571.
45. Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13:549-560.
46. Ortmann R, Smeltz R, Yap G, et al. A heritable defect in IL-12 signaling in B10.Q/J mice: I. In vitro analysis. J Immunol 2001; 166:5712-5719.
47. Yap GS, Ortmann R, Shevach E, et al. A heritable defect in IL-12 signaling in B10.Q/J mice: II. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J Immunol 2001; 166:5720-5725.
48. Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100:11594-11599.
49. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19:641-644.
50. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168:5699-5708.
51. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004; 3:261-269. Phosphopeptidomimetics have long been suggested as possible modes for inhibiting SH2-phosphotyrosine interactions. This study suggests that this strategy may be useful for targeting Stats.
52. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105.
53. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005; 24:970-979
54. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100:4138-4143.
55. Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11:43-49.
56. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000; 19:2577-2584.
57. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54. This study provides data indicating that inhibiting Stat3 can promote innate immune responses.
58. Yu CL, Jove R, Burakoff SJ. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol 1997; 159:5206-5210.
59. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2:740-749.
60. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10:39-49.
61. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004; 279:821-824. This is an excellent review of the negative regulation of cytokine signaling.
62. O'Shea JJ, Watford W. A peek at PIAS. Nat Immunol 2004; 5:875-876. This is a recent review of PIAS proteins.
63. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278:1803-1805.
64. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998; 95:10626-10631.
65. Arora T, Liu B, He H, et al. PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4. J Biol Chem 2003; 278:21327-21330.
66. Rogers RS, Horvath CM, Matunis MJ. SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation. J Biol Chem 2003; 278:30091-30097.
67. Ungureanu D, Vanhatupa S, Kotaja N, et al. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 2003; 102:3311-3313.
68. Sachdev S, Bruhn L, Sieber H, et al. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001; 15:3088-3103.
69. Liu B, Mink S, Wong KA, et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 2004; 5:891-898.
70. Roth W, Sustmann C, Kieslinger M, et al. PIASy-deficient mice display modest defects in IFN and Wnt signaling. J Immunol 2004; 173:6189-6199.
71. Flowers LO, Johnson HM, Mujtaba MG, et al. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J Immunol 2004; 172:7510-7518. The first description of an engineered SOCS analog.